Producing human CD34+CD7+CD5+CD1a− progenitor T cells and method of treatment
AssigneeSunnybrook Health Sciences Centre
InventorsJuan Carlos Zuniga-Pflucker, Geneve Awong, Ross La Motte-Mohs
Life of this patent
Estimating the term…
Abstract
Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.
Claims11
A method of producing a CD34+CD7+CD5+CD1a−progenitor T cell (pro-T cell) comprising:
- (a) culturing stem cells or progenitor cells selected from the group consisting of hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells with stromal cells;
- and
- (b) determining the presence of CD34+CD7+CD5+CD1a−pro-T cells in the culture.
A method for increasing the number of T cells in a mammal comprising administering to a mammal an effective amount of a purified human progenitor T cell having a phenotype CD34+CD7+CD5+CD1a−, wherein the human progenitor T cell is produced by a method comprising
- (a) culturing stem cells or progenitor cells selected from the group consisting of hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells with stromal cells, and
- (b) determining the presence of CD34+CD7+CD5+CD1a−pro-T cells in the culture,
- wherein an increase in CD7+CD5+CD1a+pro−T cells and cells of a later T-cell development stage is detected in the mammal.
Dependencies are inferred from the claim text.